Selective potassium channel agonists and methods of use thereof are disclosed. A compound, or a pharmaceutically acceptable salt thereof, having a formula I ##STR00001##
wherein R.sup.1 is H or optionally-substituted alkyl; R.sup.2 is optionally-substituted C.sub.1-C.sub.6 alkyl or optionally-substituted cyclopropyl; R.sup.3 and R.sup.4 are each independently H or optionally-substituted alkyl; R.sup.5 is H, optionally-substituted alkyl, acyl, or alkoxycarbonyl; R.sup.6 and R.sup.7 are each independently H, optionally-substituted alkyl, or R.sup.6 and R.sup.7 together form a carbocycle; R.sup.8 is substituted phenyl or optionally-substituted pyridinyl, provided that if R.sup.8 is substituted phenyl, then R.sup.2 is optionally-substituted cyclopropyl; and R.sup.9, R.sup.10 and R.sup.11 are each independently H, halo, or optionally-substituted alkyl.

An aspect of the present invention provides an internal and the like. The internal is easily handled and is capable of yielding a satisfactory defoaming effect. An internal (50) is used in a fluidized bed reaction device (1), in which a first material and a second material are brought into contact with each other and reacted with each other. The internal (50) is attached to a ceiling part of the fluidized bed reaction device (1), and includes a plurality of chains (21).

An aspect of the present invention provides an internal and the like. The internal is easily handled and is capable of yielding a satisfactory defoaming effect. An internal (50) is used in a fluidized bed reaction device (1), in which a first material and a second material are brought into contact with each other and reacted with each other. The internal (50) is attached to a ceiling part of the fluidized bed reaction device (1), and includes a plurality of chains (21).

The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.

The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.

The present invention relates to novel compounds, pharmaceutical compositions comprising such compounds and their use for treating, alleviating or preventing diseases or disorders relating to the activity of potassium channels.

The present invention relates to novel compounds, pharmaceutical compositions comprising such compounds and their use for treating, alleviating or preventing diseases or disorders relating to the activity of potassium channels.

The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor. In certain embodiments of the methods disclosed herein, the methods include administering to the subject a compound as disclosed herein and a peripherally acting P-blocker (PABRA).

The invention relates to a compound of formula (I) ##STR00001##
wherein R.sup.1 to R.sup.3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

The invention relates to a compound of formula (I) ##STR00001##
wherein R.sup.1 to R.sup.3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.